A Potential First Treatment for Stargardt Disease

Data from the phase 3 DRAGON trial support tinlarebant as a treatment for the inherited retinal disorder. Belite Bio has completed a rolling NDA submission to the FDA.

By: Quan Dong Nguyen, MD, Diana V. Do, MD

Retinal Physician June 23, 2026

5 Key Takeaways

1

The phase 3 DRAGON trial demonstrated that tinlarebant significantly slows lesion progression in adolescent Stargardt disease.
2

Tinlarebant is administered orally at a dosage of 5 mg daily and shows positive outcomes compared to placebo.
3

The treatment exhibited no significant systemic side effects, and adverse visual phenomena were minimal.
4

Patients tolerated tinlarebant well during the study, indicating good acceptability of the treatment.
5

Belite Bio has submitted a rolling NDA to the FDA for tinlarebant, potentially marking the first treatment for Stargardt disease.

Quan Dong Nguyen

Bio: Quan Dong Nguyen, MD, is an ophthalmologist whose work discussed in Retinal Physician focuses on posterior uveitis care for retina specialists. At the retina subspecialty day at the AAO meeting, he addressed common mistakes in managing posterior uveitis, including diagnostic assumptions in referred cases, excessive testing, and safe use of systemic therapy. His discussed areas of focus include inflammatory eye disease, drug-induced ocular inflammation, systemic treatment approaches, and emerging biologics for ocular inflammatory diseases.

PentaVision

Retinal Physician

A Potential First Treatment for Stargardt Disease

5 Key Takeaways

1

2

3

4

5

Recommendations